Skip to main content

Table 2 Correlation of PIK3CA mutation and classic clinical characteristics with metastasis-free survival (MFS) in primary inflammatory breast cancer (IBC) patients with stage III disease (n = 114)

From: Targeted next-generation sequencing identifies clinically relevant somatic mutations in a large cohort of inflammatory breast cancer

Parameters

n

Univariate analysis

Multivariate analysis

HR (95% CI)

p a

HR (95% CI)

p b

Age

 

0.8 (0.5–1.1)

0.6

1.0 (0.5–1.7)

0.9

  ≤50 years

48

    

  >50 years

66

    

ER status

 

0.9 (0.6–1.6)

0.8

1.0 (0.5–2.0)

1.0

 Negative

67

    

 Positive

47

    

PR status

 

1.3 (0.8–2.3)

0.3

1.7 (0.8–3.5)

0.1

 Negative

82

    

 Positive

32

    

Her2 status

 

1.7 (1.0–2.8)

0.1

2.0 (1.1–3.8)

0.03

 Negative

79

    

 Positive

35

    

SBR grade

 

1.2 (0.7–2.0)

0.2

1.2 (0.7–2.2)

0.5

 III

71

    

 I and II

43

    

PIK3CA

 

2.6 (1.4–4.7)

0.002

2.7 (1.5–4.7)

0.001

 Mut-type

33

    

 Wild-type

81

    
  1. CI confidence interval, ER estrogen receptor, Her2 human epidermal growth factor receptor 2, HR hazard ratio, PR progesterone receptor, SBR Scarf Bloom Richardson classification
  2. a Log-rank test
  3. b Cox multivariate analyses